Company: GIFLF
Filing Date: 2025-04-11
Form Type: 20-F
Source: 0001104659-25-034245
Chunk: 111

Company: Grifols SA
Filing Date: 2025-04-11
Form: 20-F
Item: Item 4
Chunk 111
---
 the world, of which 688 are in the final application process. In some countries, these patents grant a 20-year protection period. Approximately 1,216 of these patents are set to expire in the next ten years. In terms of recent expirations, the patent for the Grifols Sterile Filling system expired in January 2024, and the patent for the process of removing viruses in Fibrinogen solutions expired in March 2024.
As of December 31, 2024, we also owned 3,601 trademarks and trademark applications in various countries throughout the world, of which 130 are in the final application process. In addition, we co-own certain patents and patent applications with third parties, including patent rights co-owned with Novartis following the Novartis Acquisition.
We maintain a department with personnel in Spain and Germany to handle the patent and trademark approval and maintenance process and to monitor possible infringements.

71

Patents for Plasma Derivative Products
As of December 31, 2024, we owned 2,175 patents and patent applications related to plasma derivatives, including 986 in Europe, 311 in the United States and Canada, and 878 in the rest of the world. The most important of these patents relate to:

●   a concentrated subcutaneous alpha-1 antitrypsin;
----------------------------------------------------

●   the use of low volume plasma exchange for the treatment of Alzheimer’s disease;
-----------------------------------------------------------------------------------

●   transferrin for neurodegenerative applications;
---------------------------------------------------

●   transferrin for the treatment of Hipoxia inducible factor related conditions;
---------------------------------------------------------------------------------

●   plasmin in wound healing;
-----------------------------

●   plasmin in organ transplantation;
-------------------------------------

●   a concentrated subcutaneous Immunoglobulin G injection;
-----------------------------------------------------------

●   concentrated Immunoglobulin M preparations for the treatment of bacterial infections;
-----------------------------------------------------------------------------------------

●   hyperimmune immunoglobulin for treatment of Covid-19;
---------------------------------------------------------

●   anti-thrombin to treat blunt trauma;
----------------------------------------

●   anti-thrombin to treat stroke;
----------------------------------

●   Mip1a as marker of effectiveness of Albumin treatment in Alzheimer disease;
-------------------------------------------------------------------------------

●   the use of plasma exchange for removal of exosomes causing neurodegenerative disease; and
---------------------------------------------------------------------------------------------

●   the use of plasma exchange for removal of exosomes causing cancer.
----------------------------------------------------------------------
Patents for Diagnostic Products and Healthcare Solutions
As of December 31, 2024, we owned 552